Synonyms: L/105 | Rifamycin L 105 | Xifaxan®
rifaximin is an approved drug (FDA (2004))
Compound class:
Synthetic organic
Comment: Rifaximin is a semisynthetic derivative of rifamycin and belongs to the ansamycin group of antibacterial compounds [1]. It has broad spectrum activity against Gram-positive and Gram-negative bacteria.
|
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2004)) |
International Nonproprietary Names | |
INN number | INN |
5244 | rifaximin |
Synonyms |
L/105 | Rifamycin L 105 | Xifaxan® |
Database Links | |
Specialist databases | |
Antibiotic DB | Rifaximin |
Other databases | |
CAS Registry No. | 80621-81-4 (source: Scifinder) |
ChEBI | CHEBI:75246 |
ChEMBL Ligand | CHEMBL1617 |
DrugBank Ligand | DB01220 |
GtoPdb PubChem SID | 464244153 |
PubChem CID | 6436173 |
RCSB PDB Ligand | RXM |
Search Google for chemical match using the InChIKey | NZCRJKRKKOLAOJ-XRCRFVBUSA-N |
Search Google for chemicals with the same backbone | NZCRJKRKKOLAOJ |
Search PubMed clinical trials | rifaximin |
Search PubMed titles | rifaximin |
Search PubMed titles/abstracts | rifaximin |
UniChem Compound Search for chemical match using the InChIKey | NZCRJKRKKOLAOJ-XRCRFVBUSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | NZCRJKRKKOLAOJ-XRCRFVBUSA-N |
Wikipedia | Rifaximin |